Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Active feminization of the preoptic area occurs independently of the gonads in Amphiprion ocellaris.

Dodd LD, Nowak E, Lange D, Parker CG, DeAngelis R, Gonzalez JA, Rhodes JS.

Horm Behav. 2019 Jun;112:65-76. doi: 10.1016/j.yhbeh.2019.04.002. Epub 2019 Apr 11.

PMID:
30959023
2.

Discovery of Modulators of Adipocyte Physiology Using Fully Functionalized Fragments.

Galmozzi A, Parker CG, Kok BP, Cravatt BF, Saez E.

Methods Mol Biol. 2018;1787:115-127. doi: 10.1007/978-1-4939-7847-2_9.

3.

Chemistry Takes Center Stage for Identifying Cancer Targetability.

Parker CG, Cravatt BF.

Cell. 2018 May 3;173(4):815-817. doi: 10.1016/j.cell.2018.04.020.

4.

Chemical Proteomics Identifies SLC25A20 as a Functional Target of the Ingenol Class of Actinic Keratosis Drugs.

Parker CG, Kuttruff CA, Galmozzi A, Jørgensen L, Yeh CH, Hermanson DJ, Wang Y, Artola M, McKerrall SJ, Josyln CM, Nørremark B, Dünstl G, Felding J, Saez E, Baran PS, Cravatt BF.

ACS Cent Sci. 2017 Dec 27;3(12):1276-1285. doi: 10.1021/acscentsci.7b00420. Epub 2017 Dec 6.

5.

Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients.

Schonhoft JD, Monteiro C, Plate L, Eisele YS, Kelly JM, Boland D, Parker CG, Cravatt BF, Teruya S, Helmke S, Maurer M, Berk J, Sekijima Y, Novais M, Coelho T, Powers ET, Kelly JW.

Sci Transl Med. 2017 Sep 13;9(407). pii: eaam7621. doi: 10.1126/scitranslmed.aam7621.

6.

Response to 'Safety issue with TT380 Slimline intrauterine contraceptive device'.

Parker CG.

J Fam Plann Reprod Health Care. 2017 Jul;43(3):242. doi: 10.1136/jfprhc-2017-101826. No abstract available.

7.

Ligand and Target Discovery by Fragment-Based Screening in Human Cells.

Parker CG, Galmozzi A, Wang Y, Correia BE, Sasaki K, Joslyn CM, Kim AS, Cavallaro CL, Lawrence RM, Johnson SR, Narvaiza I, Saez E, Cravatt BF.

Cell. 2017 Jan 26;168(3):527-541.e29. doi: 10.1016/j.cell.2016.12.029. Epub 2017 Jan 19.

8.

Clinical element models in the SHARPn consortium.

Oniki TA, Zhuo N, Beebe CE, Liu H, Coyle JF, Parker CG, Solbrig HR, Marchant K, Kaggal VC, Chute CG, Huff SM.

J Am Med Inform Assoc. 2016 Mar;23(2):248-56. doi: 10.1093/jamia/ocv134. Epub 2015 Nov 13.

9.

Illuminating HIV gp120-Ligand Recognition through Computationally-Driven Optimization of Antibody-Recruiting Molecules.

Parker CG, Dahlgren MK, Tao RN, Li DT, Douglass EF Jr, Shoda T, Jawanda N, Spasov KA, Lee S, Zhou N, Domaoal RA, Sutton RE, Anderson KS, Jorgensen WL, Krystal M, Spiegel DA.

Chem Sci. 2014 Jun 1;5(6):2311-2317.

10.
11.

Lessons learned in detailed clinical modeling at Intermountain Healthcare.

Oniki TA, Coyle JF, Parker CG, Huff SM.

J Am Med Inform Assoc. 2014 Nov-Dec;21(6):1076-81. doi: 10.1136/amiajnl-2014-002875. Epub 2014 Jul 3.

12.

Exploring binding and effector functions of natural human antibodies using synthetic immunomodulators.

Jakobsche CE, Parker CG, Tao RN, Kolesnikova MD, Douglass EF Jr, Spiegel DA.

ACS Chem Biol. 2013 Nov 15;8(11):2404-11. doi: 10.1021/cb4004942. Epub 2013 Sep 20.

13.

Transition support for the newly licensed nurse: a programme that made a difference.

Dyess S, Parker CG.

J Nurs Manag. 2012 Jul;20(5):615-23. doi: 10.1111/j.1365-2834.2012.01330.x. Epub 2012 Apr 5.

PMID:
22823217
14.

Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease.

McEnaney PJ, Parker CG, Zhang AX, Spiegel DA.

ACS Chem Biol. 2012 Jul 20;7(7):1139-51. doi: 10.1021/cb300119g. Epub 2012 Jul 3. Review.

15.

Building a robust, scalable and standards-driven infrastructure for secondary use of EHR data: the SHARPn project.

Rea S, Pathak J, Savova G, Oniki TA, Westberg L, Beebe CE, Tao C, Parker CG, Haug PJ, Huff SM, Chute CG.

J Biomed Inform. 2012 Aug;45(4):763-71. doi: 10.1016/j.jbi.2012.01.009. Epub 2012 Feb 4.

16.

An OWL meta-ontology for representing the Clinical Element Model.

Tao C, Parker CG, Oniki TA, Pathak J, Huff SM, Chute CG.

AMIA Annu Symp Proc. 2011;2011:1372-81. Epub 2011 Oct 22.

17.

What's in a name?

Parker CG.

J Fam Plann Reprod Health Care. 2010 Jan;36(1):45; author reply 45. doi: 10.1783/147118910790291073. No abstract available.

18.

An antibody-recruiting small molecule that targets HIV gp120.

Parker CG, Domaoal RA, Anderson KS, Spiegel DA.

J Am Chem Soc. 2009 Nov 18;131(45):16392-4. doi: 10.1021/ja9057647.

19.

Increase in IUD expulsions.

Parker CG.

J Fam Plann Reprod Health Care. 2007 Jan;33(1):66. No abstract available.

20.

Detailed clinical models for sharable, executable guidelines.

Parker CG, Rocha RA, Campbell JR, Tu SW, Huff SM.

Stud Health Technol Inform. 2004;107(Pt 1):145-8.

PMID:
15360792
21.
22.

Identification of stathmin as a novel substrate for p38 delta.

Parker CG, Hunt J, Diener K, McGinley M, Soriano B, Keesler GA, Bray J, Yao Z, Wang XS, Kohno T, Lichenstein HS.

Biochem Biophys Res Commun. 1998 Aug 28;249(3):791-6.

PMID:
9731215
23.
25.

Peroxidasin: a novel enzyme-matrix protein of Drosophila development.

Nelson RE, Fessler LI, Takagi Y, Blumberg B, Keene DR, Olson PF, Parker CG, Fessler JH.

EMBO J. 1994 Aug 1;13(15):3438-47.

26.

Tiggrin, a novel Drosophila extracellular matrix protein that functions as a ligand for Drosophila alpha PS2 beta PS integrins.

Fogerty FJ, Fessler LI, Bunch TA, Yaron Y, Parker CG, Nelson RE, Brower DL, Gullberg D, Fessler JH.

Development. 1994 Jul;120(7):1747-58.

27.

Structural model of porcine factor VIII and factor VIIIa molecules based on scanning transmission electron microscope (STEM) images and STEM mass analysis.

Mosesson MW, Fass DN, Lollar P, DiOrio JP, Parker CG, Knutson GJ, Hainfeld JF, Wall JS.

J Clin Invest. 1990 Jun;85(6):1983-90.

28.

pH-dependent denaturation of thrombin-activated porcine factor VIII.

Lollar P, Parker CG.

J Biol Chem. 1990 Jan 25;265(3):1688-92.

29.

Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin.

Hill-Eubanks DC, Parker CG, Lollar P.

Proc Natl Acad Sci U S A. 1989 Sep;86(17):6508-12.

30.

Subunit structure of thrombin-activated porcine factor VIII.

Lollar P, Parker CG.

Biochemistry. 1989 Jan 24;28(2):666-74.

PMID:
2496750
31.

Characterization of purified hepatitis B surface antigen containing pre-S(2) epitopes expressed in Saccharomyces cerevisiae.

Langley KE, Egan KM, Barendt JM, Parker CG, Bitter GA.

Gene. 1988 Jul 30;67(2):229-45.

PMID:
2458990
32.

Association of the factor VIII light chain with von Willebrand factor.

Lollar P, Hill-Eubanks DC, Parker CG.

J Biol Chem. 1988 Jul 25;263(21):10451-5.

33.

Molecular characterization of commercial porcine factor VIII concentrate.

Lollar P, Parker CG, Tracy RP.

Blood. 1988 Jan;71(1):137-43.

PMID:
3120820
34.

Stoichiometry of the porcine factor VIII-von Willebrand factor association.

Lollar P, Parker CG.

J Biol Chem. 1987 Dec 25;262(36):17572-6.

35.

Degradation of coagulation proteins by an enzyme from Malayan pit viper (Akistrodon rhodostoma) venom.

Lollar P, Parker CG, Kajenski PJ, Litwiller RD, Fass DN.

Biochemistry. 1987 Dec 1;26(24):7627-36.

PMID:
3322404
36.

Role of polycationic C-terminal portion in the structure and activity of recombinant human interferon-gamma.

Arakawa T, Hsu YR, Parker CG, Lai PH.

J Biol Chem. 1986 Jun 25;261(18):8534-9.

37.

Sites of phosphorylation in recombinant human interferon-gamma.

Arakawa T, Parker CG, Lai PH.

Biochem Biophys Res Commun. 1986 Apr 29;136(2):679-84.

PMID:
3010991

Supplemental Content

Loading ...
Support Center